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ABSTRACT 
Tumor suppressor protein p53 is a critical transcription factor involved in an intricate 
signaling network responsible for cell fate. In over half of all human cancers, p53 is found 
inactivated from missense mutations and is only marginally stable at physiological 
conditions. Therefore, immense research has become focused on stabilizing p53. This study 
intends to test two p53 mutants for relative stability based on prior computational predictions 
that involved a previously engineered ‘super-stable’ mutant and a simulated loop deletion 
mutant, which is predicted to be more stable. Based on protein purification observations for 
both mutants, significant differences in structural features seem apparent, even before 
detailed biophysical characterization. The significance of this study is twofold. First, this 
work may initiate similar studies to ultimately impact the reliability on computational 
predictions for molecular stability, possibly leading to a widespread use for high throughput 
analysis of biomolecules. Finally, we may be able to develop insight for additional stabilizing 
forces of p53 that may enhance therapeutic drug design for many cancer types. 
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CHAPTER 1. OVERVIEW 
1.1 Introduction 
 
Figure 1. The p53 network.  Three 
independent pathways exist that activate the 
p53 network in response to cell stress.  
 serves as a negative regulator of p53 
for proteolysis (protein 
 controlling 
gical concentrations of p53.2 
Mdm2
by tagging it 
degradation), thereby
physiolo
 
 Mutational analysis has become a key mechanism for understanding the structure-
function interplay within proteins.  In general, proteins with a relatively simple structure and 
of manageable size are often the desired features to perform mutation studies that may serve 
as a model for other protein families. With such parameters, the core domain of protein, p53, 
has received significant attention. P53 holds a multi-faceted functionality related to cell-cycle 
control and ultimately, cancer.  P53 has been referred to as a guardian of the genome, having 
evolved as a transcription factor responsible for promoting expression of the regulatory genes 
directly involved in cell-cycle arrest, apoptosis (programmed cell death), and the preclusion 
of angiogenesis.4   P53 achieves this role through its position in an intricate network that is 
elicited upon cell stress from UV light, oncogenes, and DNA damage (Fig. 1).6 Disruption of 
this hub can destroy the intimate network that supports basic cellular functions.  
1.2 Structural Features of p53.  P53 is made up of 393 amino acids within three domains: 
(1) the N-terminal domain contains transactivation activity for regulatory purposes (e.g., 
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interactions with negative regulator, Mdm2 (Fig. 1)); (2) the C-terminal domain that entails 
two sub-domains called the tetramerization domain, which modulates oligomerization, and 
an auto-regulatory domain involved in non-specific DNA binding through acetylation; and 
(3) the DNA binding domain, or core domain (p53c), that contains predominantly β-sheet 
structure and binds specific DNA sites for transcriptional control of the p53 network.2, 7, 8   
Among the three domains, p53c and the tetramerization domains are the key domains that 
provide structural insight because of their intrinsic order through -helical and β-sheet 
features. All other domains are naturally disordered and unfolded.9   
1.3 Cancerous Mutations of p53.  P53 is only marginally stable at physiological conditions 
(~6 kcal mol-1); exposing key residues to debilitating mutations.5  Mutations of the p53 gene 
are observed in almost half of all human cancers.10    
Of these cancerous mutations, the majority have been mapped to the core domain (Fig. 2).11  
The major core domain mutations (residues 175, 243, 245, 248, 249, 273, and 282) can be 
classified as either thermodynamic or contact mutants (Fig. 3).7  The DNA contact mutants 
(Arg273, Arg248, and Arg280) have been shown to slightly reduce thermodynamic stability, but 
 
Figure 2. The five highly conserved 
regions of the p53 gene across 
species are indicated by roman 
numerals. The bar graph depicts the 
predominant frequency of tumor-
derived mutations contained within 
the core domain relative to the other 
two domains.  
(Cho et al., 1994)  
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(Bullock et al., 1997) 
 
Figure 3. MOLSCRIPT1 cartoon of “hot 
spot” mutations within p53 core domain.  
Zinc-binding ligand mutants, R175H and 
C242S, have been shown to be destabilized 
by approximately ~ 3 kcal mol-1.   DNA 
contact mutation, R248Q, and structural 
mutation, R249S, are represented in 
proximity to the zinc finger motif.  Trp146 is 
the fluorescing residue used for 
denaturation experiments .3, 5   
substantially compromise DNA binding without structural perturbation.12, 13 A hybrid 
mutation that affects not only DNA contact, but also dimerization between two core domains, 
is located in the L3 loop, which contains one DNA contact residue, Arg248. 14   When 
structural mutations arise within this loop (G245S and R249S), a loss of DNA contact via 
Arg248 results in functional and enthalpic costs. Temperature-sensitive mutant, R175H, is the 
most common cancerous mutation that involves interference with three proximal zinc-
binding ligands that result in a loss of key electrostatic interactions.15 
1.4 Thermostability of p53.  The marginal stability of p53 serves as the major reason for its 
high sensitivity to mutations that result in reduced driving forces for folding to a functional 
state.  Due to the high frequency of cancerous mutations within the core domain (p53c), 
Niklova et al. have engineered a p53c mutant based on statistical analysis of conserved 
residues and a prior knowledge of rescue mutations.16 The mutant was shown to stabilize the 
core domain by 2.65 kcal mol-1.  This “super-stable” mutant has four mutations 
(M133L/V203A/N239Y/N268D) incorporated throughout the β-sheet scaffold, which has 
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been coined as the “quad mutant.”  The quad mutant consists of two second-site suppressor 
mutations previously shown to rescue DNA contact mutants, G245S and R249S (Fig. 3), 
through global stabilization.17 A subsequent study mapped these quadruple mutations to the 
full-length protein (T-p53FL) in order to perform concurrent thermodynamic studies between 
isolated quad mutant core domains (T-p53C).3  Each of the six common cancer mutations 
(1.3) were separately incorporated into the core domain and full-length protein for 
thermodynamic comparison via Differential Scanning Calorimetry (DSC) (Fig. 4). Urea-
induced denaturation studies using Trp146 (Fig. 3) as a fluorescence probe was not used since 
full-length contains three interfering N-terminus Trp residues. Their findings (Fig. 4) indicate 
a substantial influence of the core domain on overall thermostability of the full-length protein 
through similar apparent melting temperatures (Tm). For instance, when structural hot spot 
mutation, G245S, is present in full-length p53 (T-p53-G245S) and the isolated core domain 
([T-p53C]G245S), each apparent Tm are virtually the same: 47.3 ± 0.3 ºC for full-length and 
47.3 ± 0.2 ºC for the isolated core domain. Therefore, studies that use only isolated core 
 
Figure 4. Differential Scanning 
Calorimetry (DSC) thermal studies.  
Thermostable full-length p53 (T-
p53-FL) and thermostable p53 core 
domains (T-p53C) were tested for 
correlated thermostability upon 
separate mutation with hot spot 
cancerous mutations.3  
(Ang et al., 2006) 
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domains to probe the thermodynamic effects of mutations are adequately justified without a 
comparison to full-length p53.   
1.5 DNA Recognition by p53.   
The highly disordered regions of tetrameric p53 (N-terminus) and its size (170 kDa) are the 
major limitations in obtaining crystallization and NMR studies, respectively, to elucidate 
exact domain conformations upon DNA binding.  However, one study confirmed that the 
DNA binding domain (p53c) cooperatively binds in a tetrameric complex upon each domain 
specifically recognizing decameric half-site motifs 5’-Pu·Pu·Pu·C·(A/T)·(A/T)·G·Py· Py·Py·-
3’with a 0-13 base pair separation.18  The DNA recognition site acts a as a glue to form a 
dimer, which has been confirmed by NMR and mutagenesis/binding studies.19  Two types of 
protein-protein interfaces exist within p53 tetramers: (i) dimer interface between core 
domains; and (ii) tetramerization interface.  Mutations of the core domain interactions (i) 
(e.g., structural hot spot mutations, 1.3) involve highly conserved residues and are prevalent 
in many human cancers, whereas residues in the tetramerization interface (translational 
interface) show high variability.  The translational interface is thought to be modulated by the 
DNA substrate in addition to other protein interactions.14 Considering the highly conserved 
dimer interface and its major influence on DNA binding of p53, it is apparent how 
destabilizing structural mutations within the dimer interface (inter-core domain interactions) 
have a profound effect on the overall p53 structure, ultimately compromising function with 
cancerous effects.    
1.6 Computational Predictions Suggest Stabilizing Mutants.  Molecular dynamic (MD) 
simulations provide insight to structural fluctuations within molecules as a function of time 
based on a computer algorithm (e.g. CHARMM).20 A major advantage to this approach is the 
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ability to calculate properties of a molecule that are hard to measure empirically.  One study 
administered MD simulations for a comparison between C. elegans (worm) and the human 
core domain.21 C. elegans p53 (p53w), an analog to human p53 (p53h), has been shown to 
have similar DNA-binding functionality as the human p53.22  Both core domains have similar 
structural homology as well (Fig. 5).23 Therefore, this study explored the subtle structural 
differences between human and worm core domains to elucidate potential enhancements of 
stability of the human p53 core domain. The simulations (Fig. 6) indicate p53w exhibits less 
structural fluctuations relative to p53h over the same timescale (5 ns). Upon residue-specific 
simulations, the S7S8 turn in p53h is postulated to contribute substantially to the overall 
domain instability of p53h.  Therefore, shortening the S7S8 (P223A followed by a loop 
deletion of Glu224, Val225, Gly226, Ser227, and Asp228) loop is predicted to surpass wild-
type human stability. Simulations tested the loop mutant against other human core domain 
mutants, including the quad mutant (1.4), and worm. The results (Fig. 7) suggest the loop 
mutant to surpass the quad mutant in stability.  
 
Figure 5. Topological 
similarities between p53h (A) 
and p53w (B) core domains 
outlined by ribbon structures. 
Loops L1 and S7S8 are longer in 
human p53, but overall topology 
very similar.  
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Figure 6. MD simulation studies 
A) and 325K 
(B).  The plots indicate relative kinetic 
instability of p53h (black) at both 
temperatures compared to 
compare structural fluctuations over 
time for the core domains of human 
and worm p53 at 300K (
p53w (red).   
Human 
Quad Mutant 
Loop 1 mutant 
Loop S7S8 
Mutant 
1.7 Objective.  Given the prominent role of the human p53 core domain and its effects on 
full-length p53, both functionally and thermodynamically, the overarching goal of this study 
is to test both the quad mutant (1.4) and loop mutant (1.5) for relative thermodynamic 
stability via urea-induced and thermal denaturation studies; and perform biophysical studies 
using NMR, Circular Dichroism (CD) Spectroscopy, and Hydrogen/Deuterium (H/D) 
Exchange for structural characterization. In general, this study is testing for actual relative 
stabilities to corroborate computational predictions. We hope to obtain biophysical 
measurements for elucidating the features responsible for the stability variances. 
CHAPTER 2. MATERIALS AND METHODS 
2.1 p53c Gene Subcloning. The segment of the human p53 core domain gene encoding 
Worm
 
Figure 7. MD simulation studies 
compare structural fluctuations over 
time for p53 human core domain 
mutants and sults indicate 
 
worm. Re
Loop S7S8 mutant to surpass quad 
mutant in stability.   
(Pan et al., 2006) 
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residues 94-289 was synthesized using PCR for gene-overlap reassembly of 10 
oligonucleotides (Sigma-Genosys) ranging from 50 to 94 nucleotides (Table 1) with a 20-
nucleotide overlap .7 Mutations of the loop and quad mutants (Table 2) were synthesized in 
separate oligonucleotides and replaced the respective non-mutated fragment for the gene 
reassembly reaction.  Each primer was prepared to give a 100 µM stock solution in dH20. 
The gene reassembly mixture to be used in the PCR gene reassembly reaction consisted of 
each oligonucleotide to give a total volume of 50 µL (10 µM of each primer). PCR 
conditions with a PTC-200 Peltier Thermal Cycler for the gene reassembly are: 81.5 µL 
dH20, 10 µL 10x Taq Polymerase Buffer (NEB), 2.5 µL dNTP mix (25 µM of each 
nucleotide, NEB), 5 µL reassembly mixture, 1 µL Taq polymerase (NEB); denaturation- 94 
ºC, 2 min,  59 cycles consisting of  (i) denaturation 94 ºC; 30 s;  (ii) annealing 55 ºC, 45 s; 
and (iii) extension 72 ºC, 50 s. Final extension was 72 ºC for 2 min.  PCR conditions with a 
PTC-200 Peltier Thermal Cycler for the amplification of gene reassembly are: 41.5 µL dH20, 
5 µL 10x Thermopol Buffer (NEB), 1 µL dNTP mix (25 µM of each nucleotide, NEB), 1 µL 
forward primer, 1 µL reverse primer, and 1 µL Deep Vent polymerase (NEB); initial 
denaturation 94 ºC, 2 min,  29 cycles consisting of  (i) denaturation 95 ºC, 30 s;  (ii) 
annealing 62.5 ºC, 45 s; and (iii) extension 72 ºC, 60 s. Final extension was 72 ºC for 5 min. 
The gene reassembly reaction was amplified by PCR by using the oligonucleotides 5’-AAT 
AAT AAT  CAT ATG  GCG CAT CAC CAT CAC CAT CAC GGC GGC GAA AAT CTA 
TAT TTC CAA GCT AGC TCT AGC GTG CCG AGC -3’ and  5’-ATT ATT GGA TCC 
TTA CAG GTT CTC CTC TTC GGT AC-3’.  The forward primer contains an N-terminal 
fusion of 6xHis/TEV cleavage/linker sequence.  The p53c gene was digested with NdeI and 
BamHI (NEB) restriction enzymes and subcloned into pET11a containing lacI, ColE1 ori,  
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p53c human wt 
#1 5’-AGCTCTAGCGTGCCGAGCCAGAAAACCTATCAGGGCAGCTATGGCTTTCG-3’ 
 
#2  5’-CAGTGCCGGGCTATAGGTACAGGTCACGCTCTTTGCGGTGCCGCTATGCAGAAAG 
 CCCAGACGAAAGCCATAGCTGCCCTG-3’ 
 
#3 5’-GTACCTATAGCCCGGCACTGAATAAAATGTTTTGTCAGCTGGCAAAGACCTGTCCGG 
 TGCAGCTGTGGGTGGATAGCACCCCGCCAC-3’ 
      
#4 5’-CCACTTCGGTCATGTGCTGGCTCTGTTTATAAATTGCCATTGCACGCACACGGGTGCC 
 CGGTGGCGGGGTGCTATCCAC-3’ 
 
#5 5’- GCCAGCACATGACCGAAGTGGTGCGTCGTTGTCCGCATCATGAACGTTGTAGCGATAG-3’ 
     
#6 5’-GACGGAAGGTGTTACGATCATCCAGATATTCCACACGCAGATTGCCTTCCACACGAA 
 TCAGATGCTGCGGCGGTGC-3’ 
 
#7 5’-GATGATCGTAACACCTTCCGTCATAGCGTGGTTGTGCCGTATGAACCGCCGGAAGTG 
 GGCAGCGATTGTACCACCATTCACTACAACTACATG-3’ 
 
#8 5’-GGTCAGGATCGGACGACGATTCATGCCGCCCATACAGCTGCTATTACACATGTAGTT 
 GTAGTGAATGGTGGTAC-3’ 
 
#9 5’-CGTCGTCCGATCCTGACCATTATTACCCTGGAAGATAGCAGCGGCAATCTGCTGGG 
 CCGTAATAGCTTCGAGGTGCG-3’ 
 
#10 5’-CAGGTTCTCCTCTTCGGTACGACGATCACGGCCCGGACATGCACACACACGCACCT 
 CGAAGCTATTACGG-3’ 
 
p53c P223A ΔS7S8 (loop mutant) 
 #7a  5’-GATGATCGTAACACCTTCCGTCATAGCGTGGTTGTGCCGTATGAACCG CC 
 ACCATTCACTACAACTACATG-3’ 
 
P53c Quad Mutant 
#3q 5’-GTACCTATAGCCCGGCACTGAATAAA GCAAAGACCTGTCCGGT 
 GCAGCTGTGGGTGGATAGCACCCCGCCAC-3’ 
 
#6q 5’-GACGGAAGGTGTTACGATCATCCAGATATTC CAGATTGCCTTCCACACGAAT 
 CAGATGCTGCGGCGGTGC-3’ 
 
#8q  5’-GGTCAGGATCGGACGACGATTCATGCCGCCCATACAGCTGCT ACATGTAGTT 
 GTAGTGAATGGTGGTAC-3’ 
 
#9q 5’-CGTCGTCCGATCCTGACCATTATTACCCTGGAAGATAGCAGCGGCAATCTGCTGGGC 
 CGT TTCGAGGTGCG-3’ 
 
#10q 5’-CAGGTTCTCCTCTTCGGTACGACGATCACGGCCCGGACATGCACACACACGCACC 
 TCGAAGCT GG-3’ 
GCATGTA
CTGTTTTGTCAGCTG
CGCACG
GTAAC
GATAGC
ATCAC
Table 1. Overlap gene reassembly primers. Oligonucleotide primers for p53c gene reassembly for wt and 
mutants, mutations are indicated in red. Each primer was prepared to give a 100 µM stock solution.  
AmpR, and E. coli T7 promoter genes.  The ligated plasmid was transformed in Escherichia 
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A.  p53c wt 
SSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPP 
GTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFR 
HSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVR 
VCACPGRDRRTEEENL 
 
B.  p53c P223A ΔS7S8 (loop mutant) 
SSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPP 
GTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFR 
HSVVVPYEP TTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVR 
VCACPGRDRRTEEENL 
 
C.   P53c Quad Mutant 
SSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNK QLAKTCPVQLWVDSTPPPGT 
RVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLR YLDDRNTFRHS 
VVVPYEPPEVGSDCTTIHYNYMC CMGGMNRRPILTIITLEDSSGNLLGR
ACPGRDRRTEEENL 
AC
LFC
AE
YSS DSFEVRVC 
Table 2. Amino acid sequence for p53c wild type (A.), quad mutant (B.), and loop mutant (C.). 
Mutations are indicated in red. 
coli strain DH10B. Plasmid purification (QIAprep Spin Miniprep Kit, Qiagen) was followed 
by analytical digests with PciI restriction enzyme (NEB). The recovered plasmid, pET11a-
[p53C], was sequenced (Genewiz) using T7 promoter primer (5’-TAA TAC GAC TCA CTA 
TAG GG-3’).   
2.2 Protein Expression and Purification. Protein variants were expressed in E. coli strain 
BL21(DE3) and incubated at 37 ºC until induction with IPTG (0.10 mM) at OD600 0.7 – 1.0, 
followed by overnight growth between 25-30 ºC.  Cells were harvested by centrifugation and 
sonicated in lysis buffer (50 mM Tris•HCl, pH 8, 300 mM NaCl, 10 mM imidazole, 2 mM β-
mercaptoethanol, and 0.10 mM ZnCl).  The protein was purified using Ni2+ affinity. This was 
achieved upon addition of 50% slurry of Ni-NTA agarose (Qiagen) to supernatant after 4 ºC 
incubation for 1 h before loading on 10 mL fitted chromatography column (Bio-Rad).  Wash 
buffer (50 mM Tris•HCl pH 8, 300 mM NaCl, 20 mM imidazole, 2 mM βME, 0.10 mM 
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ZnCl) was applied to the column, followed by elution buffer (50 mM Tris•HCl pH 8, 300 
mM NaCl, 250 mM imidazole, 2 mM βME, 0.10 mM ZnCl). Protein concentration was 
determined both by spectrophotometric measures [ε280 (loop mutant) 17,210 M-1 cm-1; ε280 
(quad mutant) 18,490a M-1 cm-1) obtained from Scripps Protein Calculator] and a Bradford 
Assay (Bio-Rad).   TEV (Tobacco Etch Virus) protease cleavage reactions contained 5 mM 
DTT and varied protease aliquots in 3 h increments at temperatures ranging from 4-30 ºC.  
TEV reactions were exchanged into lysis buffer using PD-10 columns (GE Healthcare) 
followed by the aforementioned Ni2+ affinity chromatography, where the initial flow-through 
contains the His6-cleaved target protein while TEV protease binds to the column due to an 
intrinsic His6-tag.  
2.3 Circular Dichroism .  CD spectra were obtained with an AVIV 202 Circular Diochroism 
Spectrometer (AVIV Biomedical, Lakewood NJ) at the Analytical Spectroscopy Laboratory 
(The Ohio State University Chemistry Department).  Wavelength scans were obtained from 
200-400 nm, 5 s average readings, with a total of 3 scans. One mm QS cuvettes (Hellma 
Cells, Inc., Plainview, NY) were used for all studies.  Thermal melts were carried out with a 
temperature range of 25-95 ºC (1º per s). Samples were exchanged in CD buffer (50 mM 
sodium phosphate, pH 7.2, 100 mM NaCl, 1 mM ΤCEP, and 1 mM ZnCl) using PD-10 
chromatography columns (GE Healthcare) prior to CD studies.  
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CHAPTER 3. RESULTS AND DISCUSSION   
3.1 p53c Gene Subcloning. The overall cloning scheme is depicted in Figure 8.  Originally, 
an NdeI restriction site was found in the mid-section of the p53c gene that was incompatible 
with the intended cloning sites.  This restriction site was later removed by incorporating a 
silent mutation from a re-ordered oligonucleotide.  Gel electrophoresis of the PCR products 
from the gene reassemblies and amplifications are shown in Figure 9.  The analytical digest 
to confirm authentic clones involves one restriction enzyme, PciI, which provides for an 
efficient and easy digest set-up.  Both the loop and quad mutant p53c genes have been 
subcloned into pET11a.   
 
Figure 8. p53c cloning scheme. Each p53c gene variant (~650 bp) is inserted in to an overexpression vector, 
pET11a. Matching restriction sites ( ult when the cloning is a success.  
p53c variants using Taq polymerase.  B. PCR amplification of gene reassembly in A.  
PciI) res
 
Figure 9. Gel Electrophoresis: 1% agarose analytical gel. A. PCR gene reassembly of 
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3.2 Protein Expression and Purification 
3.2.1 Loop Mutant.  The loop mutant (23.8 kDa) was the first variant expressed (Fig. 10) in 
E. coli BL21(DE3) for this study. Substantial aggregation was noticed throughout 
purification. In addition, impurities (~160 kDa)  from E. coli that exhibit Ni 2+ binding 
affinity have resulted in all purifications. Attempts to cleave the N-terminal fusion His6-tag 
using TEV (Tobacco Etch Virus) protease has proved unsuccessful for the loop mutant. 
Varied temperatures, protease concentrations, and reactions times were applied.  AcTEV 
(Invitrogen) was also used, but did not produce cleavage as well.  As a potential solution, a 
TEV linker region, GSSG, was introduced between the N-terminal p53c residue and the TEV 
recognition site to potentially extend the TEV recognition site for access by the protease.  
The linker did not promote cleavage. As final alternative, TAGzyme (Qiagen) will be used to 
remove the His6-tag.  TAGZyme (Fig. 10) is a cleavage kit often used for cleaving His6-tags 
from proteins intended for structural studies when other cleavage options are not possible.  
Perhaps, the TEV protease recognition site is folding in with the protein, making TEV 
cleavage inaccessible.  
      1         2         3      4 
      1          2         3        4 
 
Figure 9. 18% SDS-PAGE. Lanes 1-3 depict 
sequential elutions from Ni2+ binding affinity 
column of p53c Loop mutant (23.8 kDa).  The 
purification results were referenced with MW-
marker, RPN-800. (lane 4).     
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Figure 10. TAGZyme cleavage scheme. DAPase enzyme cleaves dipeptides from N-terminals of proteins 
until a natural stop point is reached, as seen in A, to produce the native protein. B. For proteins that do not 
contain a DAPase natural stop point, a Gln residue is introduced at an odd position directly before the native 
protein sequence and after the His6-tag. Excess Qcyclase then converts the Gln to pyroglutamine, which 
halts DAPase cleavage. pGAPase removes the converted stop point, resulting in the native protein. 
 
 
 (Qiagen.com) 
 
 
 
 
 
 
3.2.2 Quad Mutant.   The quad mutant was the second p53c variant expressed in this study 
(Fig. 11).  Aggregation was not observed throughout purification. Surprisingly, TEV 
protease was able to cleave the His6-tag from the N-terminus. However, expression levels are 
relatively low compared to the loop mutant.  
 
Figure 11. 18% SDS-PAGE of p53c quad 
expression and purification. Lane 5 is the uncut 
quad (24.3 kDa) and Lane 6 represents the cleaved 
quad  mutant (22.4 kDa) using TEV protease.  
Lanes 4 and 7 contain MW marker, RPN 800.  
Lanes 1-3 represent supernatant, flow-through from 
Ni-NTA column, and wash from column, 
respectively.   
1         2        3        4        5         6          7          8 
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3.3 Circular Dichroism Spectroscopy.  Circular Dichroism (CD) Spectroscopy is a useful 
tool for determining the secondary structure of a protein and performing thermal denaturation 
studies.  CD uses circularly polarized light to produce a signal with varied magnitudes based 
on biomolecular structures (e.g. β-sheets, -helices, or random coil) that have a signature 
response.  The signal indicates an average of the entire molecular population, where the 
peptide bond acts as the chromophore. CD spectrum was obtained for the quad and loop 
variants at varied concentrations (15.1 and 27.2 µM for loop; 22.6 and 26.5 µM for quad). 
The lower concentrations from each variant represent a separate stock solution from prior 
expression attempts shown to contain minimal impurities. A Bradford Assay was used to 
determine the initial concentrations of these protein solutions before concentrating down in a 
 
Figure 12. 12.5% SDS-PAGE of p53c quad (24.3 kDa) and loop 
(23.8 kDa) expression and purification. Lanes 6 and 7 represent 
loop mutant in elution and CD buffer, respectively.  Lane 8 
contains quad mutant in CD buffer.   Lanes 5 and 10 contain MW 
marker, RPN 755.  Overall impurities for each mutant is 
substantial, coupled with poor expression levels. Lanes 1-4 
represent pellet from centrifugation, supernatant, flow-through 
from Ni-NTA column, and wash, respectively, from loop 
purification. 
1         2         3      4        5       6        7        8        9       10 
 19 
YM-10 spin column.  The higher concentrations of each variant were determined by UV-Vis 
spectrophotometry in a 50 µL quartz cuvette.  Upon observing the SDS-PAGE analysis (Fig. 
12), significant impurities exist in both p53c mutant solutions. Therefore, the CD spectrum 
(Fig. 13) cannot be relied upon, as the impurities may have secondary structure causing a 
distortion in CD signal from the target protein. The loop mutant has significant impurities 
(~30 kDa). Initial thermal melts were inconclusive since the data collection was too fast (1 ºC  
per s) for meaningful data. 
    9         10 
mdeg 
 
Figure 13. CD spectrum (mdeg vs. wavelength) of p53c loop and quad mutants. Mild signals 
were produced for the wavelength scan of each variant. Although loop seems to produces the 
strongest signal, it also the least pure. Thus, this data is inconclusive for confirming the secondary 
structural attributes of each variant. 
Wavelength 
3.4 Discussion.  The core domain of p53 has significant influence on the thermodynamics of 
full-length p53. As result, mutations within this domain largely dictate either the foldedness 
or DNA-binding of this transcription factor that is centrally-positioned in a complex 
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signaling pathway responsible for cell-cycle control and ultimately, over 50% of tumor-
derived human cancers.  This study seeks to compare a previously engineered “super-stable” 
mutant, or quad mutant, with a loop mutant that is computationally predicted to surpass the 
quad mutant in stability.  The implications of this study may provide functional and structural 
insight between the effects of mutating a peripheral structural motif (loop mutant) and the β-
sheet scaffold (quad) of a fairly simple protein domain. In a broader sense, if the loop mutant 
is not only thermodynamically more stable than the previously tested quad mutant, but 
functionally active, the loop mutation may be an amenable alternative for full-length p53 
studies, which are normally limited due the wild-type marginal stability.  In addition, proving 
an increased stability of the loop mutant compared to quad, as previously predicted by MD 
simulations, may instill a certain confidence in using MD simulations as an indicator for 
actual relative stability.  Of course, more studies of this sort that tests for actual relative 
stabilities between proteins, or any other macromolecule, would provide an elevated 
confidence in using MD simulations in a high-throughput format.   
 This study has successfully expressed each p53c variant, albeit purification and 
expression optimization is still underway to provide adequate amounts of each protein 
solution at high purity.  In addition, a cleaved version (no His6-tag) of the loop is desired in 
order for accurate comparisons with prior studies that do not have this affinity tag on p53c 
variants. The anomalous TEV cleavage, or lack thereof, between the two p53c variants of 
this study is interesting.  It is possible that the His6-tag is being folded with the loop protein, 
thereby blocking the TEV recognition site for cleavage. Considering this, significant 
structural differences between the two mutants seem apparent before any biophysical 
characterization. Thus, running the various stability tests while identifying structural 
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attributes of these variants will entail both the cleaved and un-cleaved versions. Eventually, 
we hope to develop novel insight for additional forces that stabilize p53. 
3.5 Future Direction.   Expression and purification of p53c quad and loop mutants are 
currently being optimized. Cleavage of the His6-tag will be attempted with TAGZyme (3.2.1) 
for the loop mutant in order to achieve native structure prior to biophysical studies. When 
sufficient amounts of each variant are attained with adequate purity, thermal studies 
involving urea- and thermal-induced denaturation experiments will be run using CD 
spectroscopy and fluorimetry.  A Hydrogen/Deuterium exchange experiment using NMR is 
planned for each variant in order to measure backbone protection of amide protons resulting 
from a folded state or at least, secondary structure.  It is also our interest to obtain the crystal 
structure of the loop mutant, since this variant has not been characterized.  An in vivo screen 
is currently being optimized by a graduate student, Brinda Ramasubramanian, in our group to 
test the functionality of the p53c mutants. 
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